EICHORPublic-registry site landscape for NCT03387215, “Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure”, a Heart Failure, Systolic study sponsored by Intra-Cellular Therapies, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03387215 (registry record) |
| Study title | Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure |
| Sponsor | Intra-Cellular Therapies, Inc. |
| Condition(s) | Heart Failure, Systolic |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 2 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03387215.
Eichor generates a preliminary site-risk snapshot for NCT03387215 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
